Treatment for Alzheimer's Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Colorado Anschutz Medical Campus (CU-AMC), Aurora, CO
Alzheimer's Disease+2 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The overarching goal of this study is to a) assess the feasibility and preliminary validity of home-based delivery of TeleNP to patients with suspected Alzheimer's Disease (AD), referred for cognitive assessments in a Neurology Clinic; and b) elucidate whether TeleNP is equivalent to face-to-face evaluation (FF) for diagnostic adjudication of atypical versus typical AD.

Eligible Conditions

  • Alzheimer's Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Alzheimer's Disease

Study Objectives

8 Primary · 0 Secondary · Reporting Duration: Up to two years

Week 1
User experience of patient and any associated care partners for each health delivery conditions, Face-to-face evaluation (FF) and TeleNP evaluation
Week 5
Acceptability and Feasibility of Intervention Measures as measured by 4-item Acceptability and Feasibility of Intervention Measures Scale
Equivalence of Cognitive Test Results Across Testing Modalities as measured by Neuropsychological Test Mean Scores
Equivalence of Neuropsychologist Appraisal of Severity Across Testing Modalities as measured by Neuropsychologist-Determined Severity
Equivalence of Neuropsychologist Diagnosis Across Testing Modalities as measured by Neuropsychologist-Determined Diagnosis
Week 7
Acceptability and Feasibility of Intervention Measures as Measured by 19-item UTAUT questionnaire adapted to TeleNP
Up to two years
User experience of neuropsychologist for each health delivery conditions, Face-to-face evaluation (FF) and TeleNP evaluation
User experience of psychometrist for each health delivery conditions, Face-to-face evaluation (FF) and TeleNP evaluation

Trial Safety

Safety Progress

1 of 3

Other trials for Alzheimer's Disease

Trial Design

0 Treatment Group

80 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to two years
Closest Location: University of Colorado Anschutz Medical Campus (CU-AMC) · Aurora, CO
Photo of aurora 1Photo of aurora 2Photo of aurora 3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Alzheimer's Disease
0 CompletedClinical Trials

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,554 Previous Clinical Trials
1,910,448 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,348 Previous Clinical Trials
3,261,817 Total Patients Enrolled
Brianne Bettcher, PhDPrincipal InvestigatorUniversity of Colorado - Anschutz Medical Campus

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Individuals must carry a diagnosis of either suspected typical AD or atypical AD, based on the referring neurologist's diagnosis.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.